Jump to content

Milvexian

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ozzie10aaaa (talk | contribs) at 15:51, 16 January 2022 (Cleaned up using AutoEd). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Milvexian
Clinical data
Other namesBMS-986177, JNJ-70033093
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life11.4–18.1 h[1]
Identifiers
  • (9R,13S)-13-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H23Cl2F2N9O2
Molar mass626.45 g·mol−1
3D model (JSmol)
  • C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O
  • InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
  • Key:FSWFYCYPTDLKON-CMJOXMDJSA-N

Milvexian is a factor XIa inhibitor which acts as an anticoagulant. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery.[2]

References

  1. ^ Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D (September 2021). "First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor". Clinical and Translational Science. doi:10.1111/cts.13148. PMID 34558200. S2CID 237617815.
  2. ^ Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. (November 2021). "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. doi:10.1056/NEJMoa2113194. PMID 34780683. S2CID 244132392.